1
|
Dominguez I, Rios-Ibacache O, Caprile P, Gonzalez J, San Francisco IF, Besa C. MRI-Based Surrogate Imaging Markers of Aggressiveness in Prostate Cancer: Development of a Machine Learning Model Based on Radiomic Features. Diagnostics (Basel) 2023; 13:2779. [PMID: 37685317 PMCID: PMC10486695 DOI: 10.3390/diagnostics13172779] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 08/15/2023] [Accepted: 08/17/2023] [Indexed: 09/10/2023] Open
Abstract
This study aimed to develop a noninvasive Machine Learning (ML) model to identify clinically significant prostate cancer (csPCa) according to Gleason Score (GS) based on biparametric MRI (bpMRI) radiomic features and clinical information. METHODS This retrospective study included 86 adult Hispanic men (60 ± 8.2 years, median prostate-specific antigen density (PSA-D) 0.15 ng/mL2) with PCa who underwent prebiopsy 3T MRI followed by targeted MRI-ultrasound fusion and systematic biopsy. Two observers performed 2D segmentation of lesions in T2WI/ADC images. We classified csPCa (GS ≥ 7) vs. non-csPCa (GS = 6). Univariate statistical tests were performed for different parameters, including prostate volume (PV), PSA-D, PI-RADS, and radiomic features. Multivariate models were built using the automatic feature selection algorithm Recursive Feature Elimination (RFE) and different classifiers. A stratified split separated the train/test (80%) and validation (20%) sets. RESULTS Radiomic features derived from T2WI/ADC are associated with GS in patients with PCa. The best model found was multivariate, including image (T2WI/ADC) and clinical (PV and PSA-D) information. The validation area under the curve (AUC) was 0.80 for differentiating csPCa from non-csPCa, exhibiting better performance than PI-RADS (AUC: 0.71) and PSA-D (AUC: 0.78). CONCLUSION Our multivariate ML model outperforms PI-RADS v2.1 and established clinical indicators like PSA-D in classifying csPCa accurately. This underscores MRI-derived radiomics' (T2WI/ADC) potential as a robust biomarker for assessing PCa aggressiveness in Hispanic patients.
Collapse
Affiliation(s)
- Ignacio Dominguez
- Department of Radiology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile;
| | - Odette Rios-Ibacache
- Institute of Physics, Pontifical Catholic University of Chile, Av. Vicuña Mackenna 4860, Macul, Santiago 7820436, Chile;
- Medical Physics Unit, McGill University, Montreal, QC H4A 3J1, Canada
| | - Paola Caprile
- Institute of Physics, Pontifical Catholic University of Chile, Av. Vicuña Mackenna 4860, Macul, Santiago 7820436, Chile;
- Millennium Institute for Intelligent Healthcare Engineering, iHEALTH, ANID, Macul, Santiago 7820436, Chile
| | - Jose Gonzalez
- School of Medicine, Pontifical Catholic University of Chile, Santiago 8320000, Chile
| | - Ignacio F. San Francisco
- Department of Urology, School of Medicine, Pontifical Catholic University of Chile, Santiago 8320000, Chile
| | - Cecilia Besa
- Department of Radiology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile;
- Millennium Institute for Intelligent Healthcare Engineering, iHEALTH, ANID, Macul, Santiago 7820436, Chile
| |
Collapse
|
2
|
Dominguez I, Cruz-Gamero JM, Corasolla V, Dacher N, Rangasamy S, Urbani A, Narayanan V, Rebholz H. Okur-Chung neurodevelopmental syndrome-linked CK2α variants have reduced kinase activity. Hum Genet 2021; 140:1077-1096. [PMID: 33944995 DOI: 10.1007/s00439-021-02280-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Accepted: 03/31/2021] [Indexed: 12/22/2022]
Abstract
The Okur-Chung neurodevelopmental syndrome, or OCNDS, is a newly discovered rare neurodevelopmental disorder. It is characterized by developmental delay, intellectual disability, behavioral problems (hyperactivity, repetitive movements and social interaction deficits), hypotonia, epilepsy and language/verbalization deficits. OCNDS is linked to de novo mutations in CSNK2A1, that lead to missense or deletion/truncating variants in the encoded protein, the protein kinase CK2α. Eighteen different missense CK2α mutations have been identified to date; however, no biochemical or cell biological studies have yet been performed to clarify the functional impact of such mutations. Here, we show that 15 different missense CK2α mutations lead to varying degrees of loss of kinase activity as recombinant purified proteins and when mutants are ectopically expressed in mammalian cells. We further detect changes in the phosphoproteome of three patient-derived fibroblast lines and show that the subcellular localization of CK2α is altered for some of the OCNDS-linked variants and in patient-derived fibroblasts. Our data argue that reduced kinase activity and abnormal localization of CK2α may underlie the OCNDS phenotype.
Collapse
Affiliation(s)
- I Dominguez
- Department of Medicine, Boston University School of Medicine, Boston, MA, 02118, USA
| | - J M Cruz-Gamero
- Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR S1266, INSERM, Université de Paris, Paris, France
| | - V Corasolla
- Laboratorio di Proteomica e Metabonomica, CERC-Fondazione S.Lucia, Via del Fosso di Fiorano 64, 00143, Roma, Italy
| | - N Dacher
- Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR S1266, INSERM, Université de Paris, Paris, France
| | - S Rangasamy
- Translational Genomics Research Institute (TGen), Phoenix, AZ, 85004, USA
| | - A Urbani
- Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168, Roma, Italy.,Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168, Roma, Italy
| | - V Narayanan
- Translational Genomics Research Institute (TGen), Phoenix, AZ, 85004, USA
| | - H Rebholz
- Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR S1266, INSERM, Université de Paris, Paris, France. .,Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168, Roma, Italy. .,GHU Psychiatrie et Neurosciences, Paris, France. .,Center of Neurodegeneration, Faculty of Medicine, Danube Private University, Krems, Austria.
| |
Collapse
|
3
|
Reyes-Torres M, Oviedo-Ocaña ER, Dominguez I, Komilis D, Sánchez A. A systematic review on the composting of green waste: Feedstock quality and optimization strategies. Waste Manag 2018; 77:486-499. [PMID: 29709309 DOI: 10.1016/j.wasman.2018.04.037] [Citation(s) in RCA: 70] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/03/2017] [Revised: 04/11/2018] [Accepted: 04/25/2018] [Indexed: 06/08/2023]
Abstract
Green waste (GW) is an important fraction of municipal solid waste (MSW). The composting of lignocellulosic GW is challenging due to its low decomposition rate. Recently, an increasing number of studies that include strategies to optimize GW composting appeared in the literature. This literature review focuses on the physicochemical quality of GW and on the effect of strategies used to improve the process and product quality. A systematic search was carried out, using keywords, and 447 papers published between 2002 and 2018 were identified. After a screening process, 41 papers addressing feedstock quality and 32 papers on optimization strategies were selected to be reviewed and analyzed in detail. The GW composition is highly variable due to the diversity of the source materials, the type of vegetation, and climatic conditions. This variability limits a strict categorization of the GW physicochemical characteristics. However, this research established that the predominant features of GW are a C/N ratio higher than 25, a deficit in important nutrients, namely nitrogen (0.5-1.5% db), phosphorous (0.1-0.2% db) and potassium (0.4-0.8% db) and a high content of recalcitrant organic compounds (e.g. lignin). The promising strategies to improve composting of GW were: i) GW particle size reduction (e.g. shredding and separation of GW fractions); ii) addition of energy amendments (e.g. non-refined sugar, phosphate rock, food waste, volatile ashes), bulking materials (e.g. biocarbon, wood chips), or microbial inoculum (e.g. fungal consortia); and iii) variations in operating parameters (aeration, temperature, and two-phase composting). These alternatives have successfully led to the reduction of process length and have managed to transform recalcitrant substances to a high-quality end-product.
Collapse
Affiliation(s)
- M Reyes-Torres
- Escuela de Ingeniería Civil, Facultad de Ingeniería Físicomecánicas, Universidad Industrial de Santander, Carrera 27 Calle 9, Bucaramanga, Colombia
| | - E R Oviedo-Ocaña
- Escuela de Ingeniería Civil, Facultad de Ingeniería Físicomecánicas, Universidad Industrial de Santander, Carrera 27 Calle 9, Bucaramanga, Colombia
| | - I Dominguez
- Escuela de Ingeniería Civil, Facultad de Ingeniería Físicomecánicas, Universidad Industrial de Santander, Carrera 27 Calle 9, Bucaramanga, Colombia
| | - D Komilis
- Dept. Of Environmental Engineering, Democritus University of Thrace, Xanthi 67132, Greece; Composting Research Group, Department of Chemical Engineering, Universitat Autònoma de Barcelona, 08193-Barcelona, Bellaterra, Spain.
| | - A Sánchez
- Composting Research Group, Department of Chemical Engineering, Universitat Autònoma de Barcelona, 08193-Barcelona, Bellaterra, Spain
| |
Collapse
|
4
|
Oviedo-Ocaña ER, Torres-Lozada P, Marmolejo-Rebellon LF, Torres-López WA, Dominguez I, Komilis D, Sánchez A. A systematic approach to evaluate parameter consistency in the inlet stream of source separated biowaste composting facilities: A case study in Colombia. Waste Manag 2017; 62:24-32. [PMID: 28215974 DOI: 10.1016/j.wasman.2017.02.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/01/2016] [Revised: 01/24/2017] [Accepted: 02/06/2017] [Indexed: 06/06/2023]
Abstract
Biowaste is commonly the largest fraction of municipal solid waste (MSW) in developing countries. Although composting is an effective method to treat source separated biowaste (SSB), there are certain limitations in terms of operation, partly due to insufficient control to the variability of SSB quality, which affects process kinetics and product quality. This study assesses the variability of the SSB physicochemical quality in a composting facility located in a small town of Colombia, in which SSB collection was performed twice a week. Likewise, the influence of the SSB physicochemical variability on the variability of compost parameters was assessed. Parametric and non-parametric tests (i.e. Student's t-test and the Mann-Whitney test) showed no significant differences in the quality parameters of SSB among collection days, and therefore, it was unnecessary to establish specific operation and maintenance regulations for each collection day. Significant variability was found in eight of the twelve quality parameters analyzed in the inlet stream, with corresponding coefficients of variation (CV) higher than 23%. The CVs for the eight parameters analyzed in the final compost (i.e. pH, moisture, total organic carbon, total nitrogen, C/N ratio, total phosphorus, total potassium and ash) ranged from 9.6% to 49.4%, with significant variations in five of those parameters (CV>20%). The above indicate that variability in the inlet stream can affect the variability of the end-product. Results suggest the need to consider variability of the inlet stream in the performance of composting facilities to achieve a compost of consistent quality.
Collapse
Affiliation(s)
- E R Oviedo-Ocaña
- Escuela de Ingeniería Civil, Faculta de Ingeniería Físico-mecánica, Universidad Industrial de Santander, Carrera 27 Calle 9, Bucaramanga, Colombia
| | - P Torres-Lozada
- Escuela de Recursos Naturales y del Ambiente, Facultad de Ingeniería, Universidad del Valle, A.A. 25360- Cali, Colombia
| | - L F Marmolejo-Rebellon
- Escuela de Recursos Naturales y del Ambiente, Facultad de Ingeniería, Universidad del Valle, A.A. 25360- Cali, Colombia
| | - W A Torres-López
- Escuela de Estadística, Facultad de Ingeniería, Universidad del Valle, A.A. 25360- Cali, Colombia
| | - I Dominguez
- Escuela de Ingeniería Civil, Faculta de Ingeniería Físico-mecánica, Universidad Industrial de Santander, Carrera 27 Calle 9, Bucaramanga, Colombia
| | - D Komilis
- Composting Research Group, Department of Chemical Engineering, Universitat Autònoma de Barcelona, 08193 Barcelona, Bellaterra, Spain.
| | - A Sánchez
- Composting Research Group, Department of Chemical Engineering, Universitat Autònoma de Barcelona, 08193 Barcelona, Bellaterra, Spain
| |
Collapse
|
5
|
Depuydt J, Baeyens A, Barnard S, Beinke C, Benedek A, Beukes P, Buraczewska I, Darroudi F, De Sanctis S, Dominguez I, Monteiro Gil O, Hadjidekova V, Kis E, Kulka U, Lista F, Lumniczky K, M’kacher R, Moquet J, Obreja D, Oestreicher U, Pajic J, Pastor N, Popova L, Regalbuto E, Ricoul M, Sabatier L, Slabbert J, Sommer S, Testa A, Thierens H, Wojcik A, Vral A. O42. Realizing the European Network of Biological Dosimetry ‘RENEB’: Results of 2 intercomparison exercises for the micronucleus assay. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.07.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
6
|
Sedra F, Lee R, Dominguez I, Wilson L. Neurological complications using a novel retractor system for direct lateral minimally invasive lumbar interbody fusion. J Clin Neurosci 2016; 31:81-7. [PMID: 27349467 DOI: 10.1016/j.jocn.2016.02.031] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2015] [Revised: 02/09/2016] [Accepted: 02/14/2016] [Indexed: 10/21/2022]
Abstract
We describe our experience using the RAVINE retractor (K2M, Leesburg, VA, USA) to gain access to the lateral aspect of the lumbar spine through a retroperitoneal approach. Postoperative neurological adverse events, utilising the mentioned retractor system, were recorded and analysed. We included 140 patients who underwent minimally invasive lateral lumbar interbody fusion (MI-LLIF) for degenerative spinal conditions between 2011 and 2015 at two major spinal centres. A total of 228 levels were treated, 35% one level, 40% two level, 20% three level and 5% 4 level surgeries. The L4/5 level was instrumented in 28% of cases. 12/140 patients had postoperative neurological complications. Immediately after surgery, 5% of patients (7/140) had transient symptoms in the thigh ranging from sensory loss, pain and paraesthesia, all of which recovered within 12weeks following surgery. There were five cases of femoral nerve palsy (3.6% - two ipsilateral and three contralateral), all of which recovered completely with no residual sensory or motor deficit within 6months. MI-LLIF done with help of the described retractor system has proved a safe and efficient way to achieve interbody fusion with minimal complications, mainly nerve related, that recovered quickly. Judicious use of the technique to access the L4/5 level is advised.
Collapse
Affiliation(s)
- Fady Sedra
- Spinal Unit, Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex HA7 4LP, UK.
| | - Robert Lee
- Spinal Unit, Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex HA7 4LP, UK
| | | | - Lester Wilson
- Spinal Unit, Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex HA7 4LP, UK
| |
Collapse
|
7
|
Elío I, Sumalla S, Dominguez I, Jarrin S, Montejo M, Battino M. PP194-MON ASSESSING THE NUTRITIONAL INTAKE AND THE PROFILE OF A LATIN AMERICAN GROUP OF NUTRITION POSTGRADUATE STUDENTS. Clin Nutr 2013. [DOI: 10.1016/s0261-5614(13)60504-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Iñarrairaegui M, Pardo F, Bilbao J, Rotellar F, Benito A, D'Avola D, Herrero J, Rodriguez M, Martí P, Zozaya G, Dominguez I, Quiroga J, Sangro B. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol 2012; 38:594-601. [DOI: 10.1016/j.ejso.2012.02.189] [Citation(s) in RCA: 84] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2011] [Revised: 01/18/2012] [Accepted: 02/27/2012] [Indexed: 12/13/2022] Open
|
9
|
Dominguez I, Boni V, Garcia-Velloso MJ, Lopez-Vega JM, Martinez P, Plazaola A, Llombart A, Anton A, Galve E, Alvarez IM, Hernando B, Sanchez-Gomez R, Illarramendi JJ, Morales S, De JA, Richter JA, Lahuerta A, Garcia-Gonzalez M, Lao RJ, Puertolas T, Scherer S, Sabariz L, Garcia-Foncillas J. P2-09-02: Predicting Response to Bevacizumab in Primary Breast Cancer Using 18F-Fluorothymidina (FLT) and 18F-Misonidazole (MISO) Positron Emission/Computed Tomography (PET/CT) as Imaging Biomarkers. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-09-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: To investigate the hypothesis that early changes in tumor proliferation and hypoxic status induced by bevacizumab and assessed by imaging biomarkers might predict response to bevacizumab therapy.
Methods: 73 chemotherapy naïve, stage II-III breast cancer (BC) patients (pts) were enrolled in the training set of this phase II, single-arm, multicenter and prospective clinical trial from October 2009 until November 2010. Pts received single infusion of bevacizumab (15 mg/kg) (C1) 3 weeks prior to the beginning of neoadjuvant chemotherapy (NAC) consisting in 4 cycles of docetaxel (60 mg/mq), doxorubicin (50 mg/mq) and bevacizumab (15 mg/kg) every 21 days (C2-C5) following by surgery. Tumor proliferation and hypoxic status were evaluated using FLT and MISO PET/CT at baseline and 14–21 days after bevacizumab (C1). Standardized uptake values (SUV) for FLT and MISO and ratios to reference tissues, mediastinum (T/Me) or muscle (T/Mu), for MISO were calculated. Pathological response on surgical specimens was assessed according to Miller/Payne grading system. Pts with reduction in tumor cells >30% (G3-G4-G5) or <30% (G1-G2) were respectively considered as responders and no-responders. Association between pathological response, baseline and changes induced by bevacizumab (C1) in imaging biomarkers was analyzed using Mann-Whitney test. Receiver operating characteristic (ROC) curve was performed to test sensitivity and specificity of the biomarker found associated to response. Its value as independent predictor was tested in multivariate analysis using logistic regression. Results: Median baseline MISO and FLT SUV values in tumors were 1.2 (range 0.69−2.39) and 2.89 (range 0.97−7.18). Significant change after C1 was observed in FLT (2.7 vs 1.8, p<0.001) but no in MISO uptake. Fifty-two (74%) pts achieved response (G3-G4-G5) whether 18 (24%) were considered as no responder (G1-G2); for 3 (4%) patients Miller/Payne tumor evaluation was not available. Response showed a trend toward an association with negative estrogen receptors (ER) expression (p=0.08) and triple negative tumors (11/73) (p=0.05). FLT SUV baseline and changes after C1 in MISO SUV, T/Mu and T/Me were all significantly associated with pathological response (p=0.057, 0.03, 0.016, 0.010). ER expression and T/Mu change remained significantly associated with response in multivariate analysis (OR=24.8, IC95% 1.8-334, p=0.01 and OR=0.95, IC 95% 0.92−0.99, p value=0.02). Decrease in MISO T/Mu uptake >20% yielded a ROC curve area of 0.7 (95% CI: 0.56 - 0.85) with 94% sensitivity and 87% specificity. Conclusion: Bevacizumab determined a marked decrease in tumor proliferation. Interestingly, a decrease greater than 20% in tumor hypoxic status after C1 and assessed by MISO was found significantly associated with pathological response suggesting a potential value of early decrease in hypoxic tumor status as predictive biomarker of response. Bevacizumab, causing normalization of the tumor microvasculature, seems to potentiate the effect of cytotoxic agents on primary BC. A validation set is warranted to confirm these findings.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-09-02.
Collapse
Affiliation(s)
- I Dominguez
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - V Boni
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - MJ Garcia-Velloso
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - JM Lopez-Vega
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - P Martinez
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - A Plazaola
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - A Llombart
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - A Anton
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - E Galve
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - IM Alvarez
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - B Hernando
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - R Sanchez-Gomez
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - JJ Illarramendi
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - S Morales
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - Juan A De
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - JA Richter
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - A Lahuerta
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - M Garcia-Gonzalez
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - Romera J Lao
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - T Puertolas
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - S Scherer
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - Luis Sabariz
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - J Garcia-Foncillas
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| |
Collapse
|
10
|
Boni V, Pina LJ, Hernando B, Lopez-Vega JM, Calvo EG, Plazaola A, Morales S, Anton A, Sanchez-Gomez RM, Alvarez I, Illarramendi JJ, De JA, Martinez P, Llombart A, La HA, Dominguez I, Garcia-Velloso MJ, Garcia-Gonzalez M, Lao RJ, Puertolas T, Scherer S, Sabariz L, Garcia-Foncillas J. P2-08-05: Use of Dynamic Contrast-Enhanced MR Imaging To Predict Pathological Response in Primary Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-08-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: To investigate the effect of bevacizumab infusion on vascular parameters assessed by dynamic contrast-enhanced magnetic resonance (DCE-MR) imaging and to test their association with pathological response in primary breast cancer.
Materials and Methods: 73 patients (median age, 47 ys; age range, 29–70 ys) with biopsy-proven, previously untreated, primary breast cancer were recruited from October 2009 to November 2010 in this phase II, multicenter and non-randomized clinical trial. Patients (pts) received single infusion of bevacizumab (15 mg/kg) (C1) 3 weeks prior to the beginning of neoadjuvant chemotherapy consisting in 4 cycles of docetaxel (60 mg/mq), doxorubicin (50 mg/mq) and bevacizumab (15 mg/kg) every 21 days (C2-C5) following by surgery. All pts underwent DCE-MR imaging before and 14–21 days after C1. Quantitative and semiquantitative kinetic parameters were calculated at baseline and after C1, including the volume transfer constant (K(trans)), which primarily reflects the wash-in of the contrast agent, the backflow rate contrant (K(ep)), extracellular volume fraction (V(e)) and the initial area under the gadolinium concentration-time curve over 60 seconds (IAUGC(60)). Changes in the DCE-MRI kinetic parameters K(trans), K(ep), V(e) and IAUGC(60) were calculated and Wilcoxon test was used to assess significant effects induced by bevacizumab on kinetic parameters. Pathological response on surgical specimens after C5 was assessed according to Miller and Payne classification. Pts with tumor reduction >30% were considered as responders (G3-G4-G5) whether tumor reduction <30% were considered as no responders (G1-G2). DCE-MR imaging parameters and clinical-pathological characteristics were correlated with pathological response using Mann-Whitney test in univariate and logistic regression in multivariate analyses. Receiver operating curves (ROC) was used to define the best cut-off of the parameter found associated with pathological response.
Results: DCE-MRI was performed before (n=72) and after (n=71) C1. K(trans), K(ep), V(e) and IAUCG(60) values were significantly different at the baseline and after C1 (p<0.01). Median changes were, respectively, −51, −101, −52.5 and −4.8. Fifty-two (74%) pts achieved response (G3-G4-G5) after C5 whether 18 (24%) were considered as no responder (G1-G2); for 3 (4%) patients Miller/Payne tumor evaluation was not available. At univariate analysis, negative estrogen receptor (ER) status and higher post-C1 K(ep) (p=.057) showed a trend toward an association with response. At multivariate analysis, only ER status remains a significant predictor of response (p= .04). Area under ROC curve for K(ep) was 0.65 (IC95% 0.05−0.8, p=.057)
Conclusion: Bevacizumab affects tumor vasculature, perfusion and permeability as showed by the significantly reduction in all kinetic vasculature parameters obtained in DCE-MR imaging after C1. However, in our population these changes were not associated with pathological response. On the other hand, backflow rate constant, K(ep), a perfusion-related parameter derived from DCE-MRI yielded after C1 major than 80, may be associated with higher pathological response with a specificity of 88% and sensitivity of 90%. Future studies are warranted to confirm these findings.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-08-05.
Collapse
Affiliation(s)
- V Boni
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - LJ Pina
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - B Hernando
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - JM Lopez-Vega
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - EG Calvo
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - A Plazaola
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - S Morales
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - A Anton
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - RM Sanchez-Gomez
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - I Alvarez
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - JJ Illarramendi
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - Juan A De
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - P Martinez
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - A Llombart
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - Huerta A La
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - I Dominguez
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - MJ Garcia-Velloso
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - M Garcia-Gonzalez
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - Romera J Lao
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - T Puertolas
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - S Scherer
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - L Sabariz
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| | - J Garcia-Foncillas
- 1Clinic University of Navarra, Pamplona, Navarra, Spain; Hospital Marques de Valdecilla; Hospital Civil de Basurto; Onkologikoa; Hospital General Yagues de Burgos; Hospital Arnau de Vilanova de Lleida; Hospital Miguel Servet; Hospital de San Millan, Logroño; Hospital Donostia; Hospital de Navarra; Roche Basel; Roche Madrid
| |
Collapse
|
11
|
Garcia-Foncilla J, Garcia-Velloso MJ, Dominguez I, Morales S, Hernando B, Sanchez R, Alvarez I, Anton A, Illarramendi JJ, De JA, Martinez P, Lahuerta A, Llombart A, Garcia-Gonzalez M, Lao RJ, Purtolas T, Scherer S, Sabariz L, Lopez-Vega JM, Galve E, Plazaola A, Boni V. P5-13-04: Changes in Phosphorylation Status at VEGFR2 and Basal Tumor Hypoxic Volume Assessed by Misonidazol (MISO) Positron Emission Tomography (PET/CT) as Potential Biomarkers for Predicting Response to Bevacizumab in Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-13-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: To evaluate the expression of novel putative biomarkers as predictors of benefit from bevacizumab in stage II-III, previously untreated breast cancers (BC) patients (pts) in the context of a phase II, single-arm, multicenter and prospective clinical trial. To address this aim, we examined baseline and induced changes after a single bevacizumab administration as potential early predictors of response. Methods: Pts received a single infusion of bevacizumab (15 mg/kg) (C1) 3 weeks prior to the beginning of neoadjuvant chemotherapy consisting in 4 cycles of docetaxel (60 mg/mq), doxorubicin (50 mg/mq) and bevacizumab (15 mg/kg) every 21 days (C2-C5) following by surgery. Early assessment of tumor changes was performed by paired tumor-biopsies and MISO PET/CT before and 14–21 days after bevacizumab administration (C1). Biomarker expression was assessed by immunohistochemistry (IHC) (Ki67, CD31, CD31/Ki67, VEGFR2, pVEGFR2 [Y951]) on formalin-fixed, paraffin-embedded tissue before and after bevacizumab infusion (C1). MISO SUV and tumor volume depicted by PET were calculated. Pathological response on surgical specimens was assessed according to Miller/Payne classification. Pts with tumor reduction >90% were considered as best responders (G4-G5) whether tumor reduction <90% were considered as no responders. Association between pathological response, IHC and MISO biomarkers was analyzed using Mann-Whitney test. ROC curve was performed to test sensibility and specificity of the biomarker found significantly associated with response and its value as independent predictor was tested in the multivariate analysis using logistic regression.
Results: This analysis was performed on the training set including 73 patients (49 yr, range 29–70). Twenty (27%) patients obtained best response (G4-G5) whether 50 (68%) were considered as no responder (G1-G2-G3). Response was associated with negative estrogen receptors expression (p=0.02) and high Ki67 basal and after C1 expression (p=0.009 and p=0.01). Six (54%) of triple negative tumors were responders (p=0.05). Interestingly, change in pVEGFR2 [Y951] staining induced by bevacizumab administration and basaline MISO tumor volume was found significantly associated with response (p=0.03 and 0.057). Decrease in the phosphorilation status of VEGFR2 (Y951) >70% yielded a receiver operating characteristic (ROC) curve area of 0.681 (95% CI: 0.536 — 0.825) with 84% sensitivity and 95% specificity. The positive and negative predictive values for this marker were 60% and 64%, respectively. The change in phosphorilation status of VEGFR2p remains a significant predictor biomarker of response in multivariate analysis (OR=0.9, IC%95 0.96−0.99, p=0.04) after adjusting for clinical-pathological characteristics.
Conclusion: These findings underline the potential value of early decrease in phosphorilation status of VEGFR2 after bevacizumab infusion as predictive biomarker of response to anti-angiogenic therapy in breast cancer. Moreover, tumor hypoxic volume obtained by MISO might be associated with response. A validation set is warranted to confirm these findings.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-13-04.
Collapse
Affiliation(s)
- J Garcia-Foncilla
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - MJ Garcia-Velloso
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - I Dominguez
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - S Morales
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - B Hernando
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - R Sanchez
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - I Alvarez
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - A Anton
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - JJ Illarramendi
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - Juan A De
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - P Martinez
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - A Lahuerta
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - A Llombart
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - M Garcia-Gonzalez
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - Romera J Lao
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - T Purtolas
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - S Scherer
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - Luis Sabariz
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - JM Lopez-Vega
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - E Galve
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - A Plazaola
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| | - V Boni
- 1Clinic University of Navarra; Hospital Arnau Vilanova, Lleida; Hospital de Burgos; Hospital de La Rioja; Hospital Donosti; Hospital Miguel Servet; ; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Roche Basel; Roche Madrid
| |
Collapse
|
12
|
Lopez-Vega JM, Calvo EG, Plazaola A, Hernando B, Morales Murillo S, Anton A, Gomez RMS, Alvarez I, Illarramendi JJ, De Juan A, Martinez P, Llombart A, Scherer SJ, Sabariz L, la Huerta A, Pina LJ, Dominguez I, Garcia Velloso MJ, Boni V, Garcia-Foncillas J. Integrative and multidisciplinary clinical trial using imaging, molecular, and dynamic biomarkers to predict bevacizumab plus chemotherapy response in breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Boni V, Dominguez I, Garcia Velloso MJ, Lopez-Vega JM, Martinez P, Plazaola A, Hernando B, Llombart Cussac A, Lao J, Gomez RMS, Alvarez I, Illarramendi JJ, Calvo EG, Morales Murillo S, Puertolas T, Pina LJ, Bernedo E, Palacios G, Scherer SJ, Garcia-Foncillas J. Bevacizumab changes in patients with naïve, stage II-III breast cancer assessed by 18F-fluoromisonidazole and 18F-fluorotymidine PET-CT. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Agócs A, Alfaro R, Barnaföldi G, Bellwied R, Bencze G, Berényi D, Boldizsár L, Cuautle E, De Cataldo G, Di Bari D, Di Mauro A, Dominguez I, Futó E, García E, Hamar G, Harris J, Harton A, Kovács L, Lévai P, Lipusz C, Markert C, Martinengo P, Martinez M, Mastromarco M, Mayani D, Molnár L, Nappi E, Ortiz A, Paić G, Pastore C, Patino M, Perini D, Perrino D, Peskov V, Pinsky L, Piuz F, Pochybovâ S, Smirnov N, Song J, Timmins A, Varga D, Vargas A, Vergara S, Volpe G, Yi J, Yoo I. VHMPID: a new detector for the ALICE experiment at LHC. EPJ Web of Conferences 2011. [DOI: 10.1051/epjconf/20111303004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
15
|
Dominguez I, Sonenshein GE, Seldin DC. Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer. Cell Mol Life Sci 2009; 66:1850-7. [PMID: 19387549 PMCID: PMC3905806 DOI: 10.1007/s00018-009-9153-z] [Citation(s) in RCA: 133] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
CK2 is a highly conserved tetrameric serine/ threonine kinase present in all eukaryotic organisms. It is constitutively active, and appears to be regulated by level of expression and activity, and subcellular localization. In turn, it has been postulated to control the function of many proteins through changes in phosphorylation that affect protein stability, protein-protein interactions, and subcellular localization. Through these mechanisms, CK2 regulates many fundamental cellular properties. An enzyme that carries out such a master regulatory function is likely to be important in organismic development and in cancer. We have shown that overexpression of CK2 catalytic subunits is capable of promoting tumorigenesis, and that loss of CK2 catalytic subunits in development can be lethal. Through studies in cells, mice, and frogs, we and others have identified the Wnt and NF-kappaB pathways as two key signal transduction pathways that are regulated by CK2 activity, in embryonic development and in cancer. These results suggest that inhibiting CK2 could be useful in treating cancer, but dangerous to developing organisms.
Collapse
Affiliation(s)
- I. Dominguez
- Section of Hematology-Oncology, Department of Medicine, Boston University School of Medicine and Boston Medical Center, 650 Albany Street, Boston, Massachusetts 02118 USA
| | - G. E. Sonenshein
- Section of Hematology-Oncology, Department of Medicine, Boston University School of Medicine and Boston Medical Center, 650 Albany Street, Boston, Massachusetts 02118 USA
| | - D. C. Seldin
- Section of Hematology-Oncology, Department of Medicine, Boston University School of Medicine and Boston Medical Center, 650 Albany Street, Boston, Massachusetts 02118 USA
| |
Collapse
|
16
|
Dominguez I, Sharratt E, LeVea C, Wang J, Brattain M, Rajput A. 72. EGFR Activation in Isolation is Insufficient for a Metastatic Phenotype in an Orthotopic Colon Cancer Model. J Surg Res 2009. [DOI: 10.1016/j.jss.2008.11.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Ongchin M, Sharratt E, Dominguez I, LeVea C, Cheney R, Wang J, Brattain M, Rajput A. PL16. The Effects of Epidermal Growth Factor Receptor Activation and Attenuation of the TGFβ Pathway in an Orthotopic Model of Colon Cancer. J Surg Res 2009. [DOI: 10.1016/j.jss.2008.11.290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
18
|
Dominguez I, Rose R, Levea C, Sharratt E, Bullard Dunn K, Brattain M, Rajput A. P224. J Surg Res 2007. [DOI: 10.1016/j.jss.2006.12.408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
Vicario C, Marco F, Ortega L, Alcobendas M, Dominguez I, López-Durán L. Necrosis of the femoral head after fixation of trochanteric fractures with Gamma Locking Nail. A cause of late mechanical failure. Injury 2003; 34:129-34. [PMID: 12565020 DOI: 10.1016/s0020-1383(02)00171-7] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Cut-out of the lag screw after fixation of trochanteric fractures with intramedullary devices like the Gamma Locking Nail is a well documented cause of late mechanical failure. Avascular necrosis of the femoral head after trochanteric fractures is an uncommon complication and several causes have been described. As far as we know, the relation of the mechanical failure of fracture fixation and avascular necrosis of the femoral head in trochanteric fractures has never been described. We present a study of six consecutive patients who underwent arthroplasty after cut-out of the lag screw fixation of a trochanteric fracture with Gamma Locking Nail. All six femoral heads were studied histologically and a clinical retrospective study was also performed. In all cases, we found homogeneous avascular necrosis of the femoral head; in all but one, revascularisation was present in every area examined. We suggest that after fixation of these trochanteric fractures with the Gamma Locking Nail, there is a transitory ischaemia, if the revascularisation is not enough to provide a strong support for the lag screw, it may result in late mechanical failure in these fractures.
Collapse
Affiliation(s)
- C Vicario
- Department of Traumatology and Orthopaedic Surgery, Hospital Clínico San Carlos, Madrid, Spain.
| | | | | | | | | | | |
Collapse
|
20
|
Affiliation(s)
- S Santolaria
- Gastroenterology Service, San Jorge Hospital, C/Martinez de Velasco s/n, 22004 Huesca, Spain.
| | | | | | | |
Collapse
|
21
|
Covington AM, Aguilar A, Covington IR, Gharaibeh M, Shirley CA, Phaneuf RA, Alvarez I, Cisneros C, Hinojosa G, Bozek JD, Dominguez I, Sant'Anna MM, Schlachter AS, Berrah N, Nahar SN, McLaughlin BM. Photoionization of metastable O+ ions: experiment and theory. Phys Rev Lett 2001; 87:243002. [PMID: 11736500 DOI: 10.1103/physrevlett.87.243002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/07/2001] [Indexed: 05/23/2023]
Abstract
High-resolution absolute experimental measurements and two independent theoretical calculations were performed for photoionization of O+ ions from the 2P(o) and 2D(o) metastable levels and from the 4S(o) ground state in the photon energy range 30-35.5 eV. This is believed to be the first comparison of experiment and theory to be reported for photoionization from metastable states of ions. While there is correspondence between the predicted and measured positions and relative strengths of the resonances, the cross-section magnitudes and fine structure are sensitive to the choice of basis states.
Collapse
Affiliation(s)
- A M Covington
- Department of Physics, MS 220, University of Nevada, Reno, Nevada 89557-0058, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Affiliation(s)
- I Dominguez
- Department of Cancer Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
| | | |
Collapse
|
23
|
Dominguez I, Green JB. Dorsal downregulation of GSK3beta by a non-Wnt-like mechanism is an early molecular consequence of cortical rotation in early Xenopus embryos. Development 2000; 127:861-8. [PMID: 10648244 DOI: 10.1242/dev.127.4.861] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Cortical rotation and concomitant dorsal translocation of cytoplasmic determinants are the earliest events known to be necessary for dorsoventral patterning in Xenopus embryos. The earliest known molecular target is beta-catenin, which is essential for dorsal development and becomes dorsally enriched shortly after cortical rotation. In mammalian cells cytoplasmic accumulation of beta-catenin follows reduction of the specific activity of glycogen synthase kinase 3-beta (GSK3beta). In Xenopus embryos, exogenous GSK3beta) suppresses dorsal development as predicted and GSK3beta dominant negative (kinase dead) mutants cause ectopic axis formation. However, endogenous GSK3beta regulation is poorly characterized. Here we demonstrate two modes of GSK3beta regulation in Xenopus. Endogenous mechanisms cause depletion of GSK3beta protein on the dorsal side of the embryo. The timing, location and magnitude of the depletion correspond to those of endogenous beta-catenin accumulation. UV and D(2)O treatments that abolish and enhance dorsal character of the embryo, respectively, correspondingly abolish and enhance GSK3beta depletion. A candidate regulator of GSK3beta, GSK3-binding protein (GBP), known to be essential for axis formation, also induces depletion of GSK3beta. Depletion of GSK3beta is a previously undescribed mode of regulation of this signal transducer. The other mode of regulation is observed in response to Wnt and dishevelled expression. Neither Wnt nor dishevelled causes depletion but instead they reduce GSK3beta-specific activity. Thus, Wnt/Dsh and GBP appear to effect two biochemically distinct modes of GSK3beta regulation.
Collapse
Affiliation(s)
- I Dominguez
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
| | | |
Collapse
|
24
|
Natarajan AT, Balajee AS, Boei JJ, Darroudi F, Dominguez I, Hande MP, Meijers M, Slijepcevic P, Vermeulen S, Xiao Y. Mechanisms of induction of chromosomal aberrations and their detection by fluorescence in situ hybridization. Mutat Res 1996; 372:247-58. [PMID: 9015143 DOI: 10.1016/s0027-5107(96)00144-3] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Fluorescence in situ hybridization (FISH) technique using chromosome specific probes has revolutionized the field of radiation cytogenetics in the last few years. Some of the new insights on the origins of radiation induced chromosome aberrations in human, mouse and Chinese hamster, using FISH are reviewed in this paper.
Collapse
Affiliation(s)
- A T Natarajan
- MGC Department of Radiation Genetics and Chemical Mutagenesis, Leiden University, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Balajee AS, Dominguez I, Bohr VA, Natarajan AT. Immunofluorescent analysis of the organization of telomeric DNA sequences and their involvement in chromosomal aberrations in hamster cells. Mutat Res 1996; 372:163-72. [PMID: 9015135 DOI: 10.1016/s0027-5107(96)00136-4] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
We have investigated the organization of telomeric TTAGGG)n repeats in the extended DNA loops of chromatin of human and hamster cells by immunofluorescent technique. In humans, telomeric repeats which are predominantly localized at the termini of all the chromosomes, have been found associated with nuclear matrix. This distribution pattern did not alter, even after the removal of 90% of the DNA from the nuclear halos by EcoRI digestion. This suggests that the telomeric sequences are tightly associated with nuclear matrix and hence cannot be solubilized by nucleases. In contrast, in Chinese hamster cells (CHO B11), a major proportion of interstitial telomeric repeats are found in the loop regions, like beads on a string, with attachments to the periphery of the nuclear matrix. Unlike in human cells, EcoRI digestion removed most of the telomeric repeats from the loop regions of Chinese hamster cells. This indicates that intrachromosomal sequences are not associated with nuclear matrix, and this finding has been further substantiated by Southern hybridization of matrix associated and loop DNA fractions of hamster cells with the (TTAGGG)n probe. The organizational differences in the telomeric repeat sequences of Chinese hamster and human cells might be due to their chromosomal location as well as their interaction with nucleoprotein complexes specific for the termini of the eukaryotic chromosomes. Furthermore, the interstitial (TTAGGG)n sequences were found to be more frequently involved in the chromosomal aberrations induced by restriction enzymes. This suggests that the intrachromosomal sites of telomeric sequences behave as hot spots for DNA damage.
Collapse
Affiliation(s)
- A S Balajee
- Department of Radiation Genetics and Chemical Mutagenesis, State University of Leiden, Netherlands
| | | | | | | |
Collapse
|
26
|
Dominguez I, Boei JJ, Balajee AS, Natarajan AT. Analysis of radiation-induced chromosome aberrations in Chinese hamster cells by FISH using chromosome-specific DNA libraries. Int J Radiat Biol 1996; 70:199-208. [PMID: 8794849 DOI: 10.1080/095530096145193] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The frequencies of chromosome aberrations induced by different doses of X-rays were determined in both splenocytes and primary lung fibroblasts of Chinese hamster by bi-colour FISH using a combination of four chromosome-specific DNA libraries. The results indicate that the X-rays induced more translocations than dicentrics in Chinese hamster cells, in which the karyotype is comprised of both metacentric and acrocentric chromosomes. These results are similar to those reported in human lymphocytes, in which the karyotype contains many metacentric chromosomes. On the contrary, in mouse, which is characterized by acrocentric chromosomes only, the frequencies of translocations and dicentrics are induced in nearly equal proportions by X-rays. The ratio of translocations to dicentrics obtained in Chinese hamster cells was approximately 1.4-1.5, which supports the importance of the karyotypic features of a species in the relative induction of translocations to dicentrics. An analysis was also made on the yield of translocations and dicentrics involving individual chromosomes and the results indicate a non-random involvement of these chromosomes in the formation of aberrations.
Collapse
Affiliation(s)
- I Dominguez
- Department of Radiation Genetics and Chemical Mutagenesis, Leiden University, The Netherlands
| | | | | | | |
Collapse
|
27
|
Abstract
The Chinese hamster genome contains a total of 18 cytologically detectable arrays of interstitial telomeric sequences. A combination of G-banding and two-colour fluorescence in situ hybridization revealed that 25 out of 27 (93%) breakpoints of spontaneously occurring terminal deletions in four immortalized Chinese hamster cell lines were located in chromosomal regions containing interstitial telomeric sequences. Each of the four immortalized Chinese hamster cell lines expressed telomerase. Radiation experiments revealed the sensitivity of interstitial telomeric sequences to radiation-induced chromosomal breakage in all telomerase-positive cell lines. However, radiation-induced chromosomal breakage at interstitial telomeric sites in non-transformed, primary Chinese hamster cells was almost non-existent. Telomerase activity in primary Chinese hamster cells was not detected. These results indirectly suggest that interstitial telomeric sites represent a favourable substrate for chromosomal healing.
Collapse
Affiliation(s)
- P Slijepcevic
- Department of Radiation Genetics and Chemical Mutagenesis, University of Leiden, Wassenaarseweg 72, NL-2300 RA Leiden, The Netherlands
| | | | | | | |
Collapse
|
28
|
Dominguez I, Itoh K, Sokol SY. Role of glycogen synthase kinase 3 beta as a negative regulator of dorsoventral axis formation in Xenopus embryos. Proc Natl Acad Sci U S A 1995; 92:8498-502. [PMID: 7667318 PMCID: PMC41184 DOI: 10.1073/pnas.92.18.8498] [Citation(s) in RCA: 258] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
The dorsoventral axis is established early in Xenopus development and may involve signaling by Wnts, a family of Wnt1-protooncogene-related proteins. The protein kinase shaggy functions in the wingless/Wnt signaling pathway, which operates during Drosophila development. To assess the role of a closely related kinase, glycogen synthase kinase 3 beta (GSK-3 beta), in vertebrate embryogenesis, we cloned a cDNA encoding a Xenopus homolog of GSK-3 beta (XGSK-3 beta). XGSK-3 beta-specific transcripts were detected by Northern analysis in Xenopus eggs and early embryos. Microinjection of the mRNA encoding a catalytically inactive form of rat GSK-3 beta into a ventrovegetal blastomere of eight-cell embryos caused ectopic formation of a secondary body axis containing a complete set of dorsal and anterior structures. Furthermore, in isolated ectodermal explants, the mutant GSK-3 beta mRNA activated the expression of neural tissue markers. Wild-type XGSK-3 beta mRNA suppressed the dorsalizing effects of both the mutated GSK-3 beta and Xenopus dishevelled, a proposed upstream signaling component of the same pathway. These results strongly suggest that XGSK-3 beta functions to inhibit dorsoventral axis formation in the embryo and provide evidence for conservation of the Wnt signaling pathway in Drosophila and vertebrates.
Collapse
Affiliation(s)
- I Dominguez
- Department of Microbiology and Molecular Genetics, Harvard Medical School, Beth Israel Hospital, Boston, MA 02215, USA
| | | | | |
Collapse
|
29
|
Lozano J, Berra E, Municio MM, Diaz-Meco MT, Dominguez I, Sanz L, Moscat J. Protein kinase C zeta isoform is critical for kappa B-dependent promoter activation by sphingomyelinase. J Biol Chem 1994; 269:19200-2. [PMID: 8034680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Recent evidence demonstrates that the protein kinase C zeta (zeta PKC) isoform is required for the activation of nuclear factor kappa B (NF-kappa B) and mitogenic signaling in Xenopus oocytes and mammalian cells. The mechanism whereby zeta PKC regulates NF-kappa B most probably involves the activation of a putative I kappa B kinase of molecular mass approximately 50 kDa, which phosphorylates and inactivates I kappa B. Tumor necrosis factor alpha (TNF alpha) and interleukin-1, besides activating the phospholipase C-mediated breakdown of phosphatidylcholine, also generate ceramide, which is produced by stimulation of sphingomyelin hydrolysis. We show here that exogenous addition of sphingomyelinase (SMase) to NIH-3T3 fibroblasts transactivates a kappa B-dependent chloramphenicol acetyltransferase reporter plasmid, to an extent similar to that produced by TNF alpha or phosphatidylcholine/phospholipase C. More importantly, the ability of SMase to stimulate this parameter is severely impaired by transfection of a zeta PKC kinase-defective dominant negative mutant, which suggests a critical role of zeta PKC in SMase signaling. In keeping with this notion, we also demonstrate here that zeta PKC is activated in vitro by ceramide and in vivo by treatment of NIH-3T3 fibroblasts with SMase.
Collapse
Affiliation(s)
- J Lozano
- Centro de Biología Molecular Severo Ochoa, Canto Blanco, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
30
|
Lozano J, Berra E, Municio M, Diaz-Meco M, Dominguez I, Sanz L, Moscat J. Protein kinase C zeta isoform is critical for kappa B-dependent promoter activation by sphingomyelinase. J Biol Chem 1994. [DOI: 10.1016/s0021-9258(17)32152-x] [Citation(s) in RCA: 345] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
31
|
Diaz-Meco MT, Dominguez I, Sanz L, Dent P, Lozano J, Municio MM, Berra E, Hay RT, Sturgill TW, Moscat J. zeta PKC induces phosphorylation and inactivation of I kappa B-alpha in vitro. EMBO J 1994; 13:2842-8. [PMID: 8026469 PMCID: PMC395165 DOI: 10.1002/j.1460-2075.1994.tb06578.x] [Citation(s) in RCA: 173] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The zeta isotype of protein kinase C (zeta PKC), a distinct PKC unable to bind phorbol esters, is required during NF-kappa B activation as well as in mitogenic signalling in Xenopus oocytes and mammalian cells. To investigate the mechanism(s) for control of cellular functions by zeta PKC, this enzyme was expressed in Escherichia coli as a fusion protein with maltose binding protein (MBP), to allow immobilization on amylose beads to study signalling proteins in cell extracts that might form complex(es) with zeta PKC. The following evidence for interaction with the NF-kappa B/I kappa B pathway was obtained. MBP-zeta PKC, but not MBP, bound and activated a potentially novel I kappa B kinase of approximately 50 kDa molecular weight able to regulate I kappa B-alpha function. Activation of the I kappa B kinase was dependent on zeta PKC enzymatic activity and ATP, suggesting that zeta PKC controls, directly or indirectly, the activity of a functionally significant I kappa B kinase. Importantly, zeta PKC immunoprecipitates from TNF-alpha-stimulated NIH-3T3 fibroblasts displayed a higher I kappa B phosphorylating activity than untreated controls, indicating the in vivo relevance of these findings. We also show here that zeta PKC associates with and activates MKK-MAPK in vitro, suggesting that one of the mechanisms whereby overexpression of zeta PKC leads to deregulation of cell growth may be accounted for at least in part by activation of the MKK-MAPK complex. However, neither MKK nor MAPK is responsible for the putative I kappa B phosphorylating activity. These data provide a decisive step towards understanding the functions of zeta PKC.
Collapse
Affiliation(s)
- M T Diaz-Meco
- Centro de Biología Molecular, CSIC-UAM, Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Sanz L, Berra E, Municio M, Dominguez I, Lozano J, Johansen T, Moscat J, Diaz-Meco M. Zeta PKC plays a critical role during stromelysin promoter activation by platelet-derived growth factor through a novel palindromic element. J Biol Chem 1994. [DOI: 10.1016/s0021-9258(17)36988-0] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
33
|
Sanz L, Berra E, Municio MM, Dominguez I, Lozano J, Johansen T, Moscat J, Diaz-Meco MT. Zeta PKC plays a critical role during stromelysin promoter activation by platelet-derived growth factor through a novel palindromic element. J Biol Chem 1994; 269:10044-9. [PMID: 8144503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Stromelysin is a metalloproteinase with the widest substrate specificity that plays a critical role in the induction of the metastatic phenotype in cancer cells. The mechanisms whereby growth factors and oncogenes control stromelysin expression are beginning to be characterized. We have recently demonstrated that protein kinase C isotypes down-regulatable by chronic exposure to phorbol esters are not involved in stromelysin gene expression in response to platelet-derived growth factor, ras oncogene, and phosphatidylcholine-hydrolyzing phospholipase C. We also identified a region in the stromelysin promoter, distinct from the 12-O-tetradecanoylphorbol-13-acetate-responsive element, responsible for the promoter activity in response to these stimulants. In this paper, we further characterize that promoter fragment and demonstrate that the region encompassing nucleotides -1218 to -1202, including the palindromic sequence ACTAGT, is necessary and sufficient for the control of stromelysin gene expression. The involvement of zeta-protein kinase C but not of c-raf in the stimulation of stromelysin promoter activity in response to platelet-derived growth factor is also demonstrated here. All these data suggest the existence of a bifurcation downstream of ras in the signaling mechanisms leading to stromelysin expression and DNA synthesis.
Collapse
Affiliation(s)
- L Sanz
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, Canto Blanco, Spain
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Arenzana-Seisdedos F, Fernandez B, Dominguez I, Jacqué JM, Thomas D, Diaz-Meco MT, Moscat J, Virelizier JL. Phosphatidylcholine hydrolysis activates NF-kappa B and increases human immunodeficiency virus replication in human monocytes and T lymphocytes. J Virol 1993; 67:6596-604. [PMID: 8411362 PMCID: PMC238097 DOI: 10.1128/jvi.67.11.6596-6604.1993] [Citation(s) in RCA: 90] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
We have tested whether breakdown of phosphatidylcholine (PC) initiated by exogenous addition of a PC-specific phospholipase C (PC-PLC) from Bacillus cereus or by endogenous overexpression of PC-PLC induces functional activation of NF-kappa B and increases human immunodeficiency virus (HIV) enhancer activity. PC-PLC-activated hydrolysis of PC was found to induce bona fide p50/p65 NF-kappa B binding activity in three different cell lines of human or murine origin. No significant changes in the turnover of other cellular phospholipids were detected in PC-PLC-treated cells. Induction of NF-kappa B by PC-PLC did not depend on de novo synthesis of proteins or autocrine secretion of either tumor necrosis factor or interleukin 1. In human monocytic and lymphoblastoid T-cell lines, induction of NF-kappa B by PC-PLC resulted in clear induction of luciferase expression vectors placed under the control of synthetic kappa B enhancers or wild type, but not kappa B-mutated, HIV long terminal repeat constructs. HIV replication was increased by PC-PLC in chronically infected monocytes and T lymphocytes. NF-kappa B activation promoted by addition of exogenous PC-PLC correlated with an intense production of diacylglycerol. However, addition of a phosphatidylinositol-specific PLC from B. cereus also induced diacylglycerol but did not activate kappa B enhancer-directed vectors. PC-PLC-induced NF-kappa B activation could not be blocked by a specific inhibitor of phorbol ester-inducible protein kinases C. These results indicate that a cellular transduction pathway, dependent on specific PC breakdown, is functional in T lymphocytes and monocytes and may be used by various transmembrane receptors to activate HIV transcription through NF-kappa B-dependent induction of the HIV enhancer.
Collapse
|
35
|
Berra E, Diaz-Meco MT, Dominguez I, Municio MM, Sanz L, Lozano J, Chapkin RS, Moscat J. Protein kinase C zeta isoform is critical for mitogenic signal transduction. Cell 1993; 74:555-63. [PMID: 7688666 DOI: 10.1016/0092-8674(93)80056-k] [Citation(s) in RCA: 327] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The requirement of protein kinase C zeta (zeta PKC) for maturation of X. laevis oocytes in response to insulin, p21ras, and phosphatidylcholine-hydrolyzing phospholipase C has recently been shown. Here we present experimental evidence demonstrating that activation of zeta PKC is not only necessary but also sufficient by itself to activate maturation in oocytes and to produce deregulation of growth control in mouse fibroblasts. Furthermore, by using a dominant kinase-defective mutant of zeta PKC, we confirm that this kinase is required for mitogenic activation in oocytes and fibroblasts. These results permit us to propose zeta PKC as a critical step downstream of p21ras in mitogenic signal transduction.
Collapse
Affiliation(s)
- E Berra
- Centro de Biología Molecular, Universidad Autonoma de Madrid, Canto Blanco, Spain
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Diaz-Meco MT, Berra E, Municio MM, Sanz L, Lozano J, Dominguez I, Diaz-Golpe V, Lain de Lera MT, Alcamí J, Payá CV, Arenzana-Seisedos F, Virelizier JL, Moscat J. A dominant negative protein kinase C zeta subspecies blocks NF-kappa B activation. Mol Cell Biol 1993; 13:4770-5. [PMID: 8336714 PMCID: PMC360103 DOI: 10.1128/mcb.13.8.4770-4775.1993] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
Nuclear factor kappa B (NF-kappa B) plays a critical role in the regulation of a number of genes. NF-kappa B is a heterodimer of 50- and 65-kDa subunits sequestered in the cytoplasm complexed to inhibitory protein I kappa B. Following stimulation of cells, I kappa B dissociates from NF-kappa B, allowing its translocation to the nucleus, where it carries out the transactivation function. The precise mechanism controlling NF-kappa B activation and the involvement of members of the protein kinase C (PKC) family of isotypes have previously been investigated. It was found that phorbol myristate acetate, (PMA) which is a potent stimulant of phorbol ester-sensitive PKC isotypes, activates NF-kappa B. However, the role of PMA-sensitive PKCs in vivo is not as apparent. It has recently been demonstrated in the model system of Xenopus laevis oocytes that the PMA-insensitive PKC isotype, zeta PKC, is a required step in the activation of NF-kappa B in response to ras p21. We demonstrate here that overexpression of zeta PKC is by itself sufficient to stimulate a permanent translocation of functionally active NF-kappa B into the nucleus of NIH 3T3 fibroblasts and that transfection of a kinase-defective dominant negative mutant of zeta PKC dramatically inhibits the kappa B-dependent transactivation of a chloramphenicol acetyltransferase reporter plasmid in NIH 3T3 fibroblasts. All these results support the notion that zeta PKC plays a decisive role in NF-kappa B regulation in mammalian cells.
Collapse
Affiliation(s)
- M T Diaz-Meco
- Centro de Biología Molecular, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Dominguez I, Sanz L, Arenzana-Seisdedos F, Diaz-Meco MT, Virelizier JL, Moscat J. Inhibition of protein kinase C zeta subspecies blocks the activation of an NF-kappa B-like activity in Xenopus laevis oocytes. Mol Cell Biol 1993; 13:1290-5. [PMID: 8423794 PMCID: PMC359014 DOI: 10.1128/mcb.13.2.1290-1295.1993] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
Nuclear factor kappa B (NF-kappa B) plays a critical role in the regulation of a large variety of cellular genes. However, the mechanism whereby this nuclear factor is activated remains to be determined. In this report, we present evidence that in oocytes from Xenopus laevis, (i) ras p21- and phospholipase C (PLC)-mediated phosphatidylcholine (PC) hydrolysis activates NF-kappa B and (ii) protein kinase C zeta subspecies is involved in the activation of NF-kappa B in response to insulin/ras p21/PC-PLC. Thus, the microinjection of either ras p21 or PC-PLC, or the exposure of oocytes to insulin, promotes a significant translocation to the nucleus of an NF-kappa B-like activity. This effect is not observed when oocytes are incubated with phorbol myristate acetate or progesterone, both of which utilize a ras p21-independent pathway for oocyte activation. These data strongly suggest a critical role of the insulin/ras p21/PC-PLC/protein kinase C zeta pathway in the control of NF-kappa B activation.
Collapse
Affiliation(s)
- I Dominguez
- Centro de Biología Molecular UAM-CSIC, Madrid, Spain
| | | | | | | | | | | |
Collapse
|
38
|
Dominguez I, Diaz-Meco MT, Municio MM, Berra E, García de Herreros A, Cornet ME, Sanz L, Moscat J. Evidence for a role of protein kinase C zeta subspecies in maturation of Xenopus laevis oocytes. Mol Cell Biol 1992; 12:3776-83. [PMID: 1508183 PMCID: PMC360243 DOI: 10.1128/mcb.12.9.3776-3783.1992] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
A number of studies have demonstrated the activation of phospholipase C-mediated hydrolysis of phosphatidylcholine (PC-PLC) both by growth factors and by the product of the ras oncogene, p21ras. Evidence has been presented indicating that the stimulation of this phospholipid degradative pathway is sufficient to activate mitogenesis in fibroblasts as well as that it is sufficient and necessary for induction of maturation in Xenopus laevis oocytes. However, the mechanism whereby PC-PLC transduces mitogenic signals triggered by growth factors or oncogenes remains to be elucidated. In this study, data are presented that show the involvement of protein kinase C zeta subspecies in the channelling of the mitogenic signal activated by insulin-p21ras-PC-PLC in Xenopus oocytes as well as the lack of a critical role of protein kinase C isotypes alpha, beta, gamma, delta, and epsilon in these pathways.
Collapse
Affiliation(s)
- I Dominguez
- Centro de Biología Molecular, CSIC-UAM, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Diaz-Meco MT, Dominguez I, Sanz L, Municio MM, Berra E, Cornet ME, Garcia de Herreros A, Johansen T, Moscat J. Phospholipase C-mediated hydrolysis of phosphatidylcholine is a target of transforming growth factor beta 1 inhibitory signals. Mol Cell Biol 1992; 12:302-8. [PMID: 1309592 PMCID: PMC364110 DOI: 10.1128/mcb.12.1.302-308.1992] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Cell growth and tumor transformation can be restrained in certain cell systems by the action of transforming growth factor beta (TGF-beta). It has been established that the mechanism whereby TGF-beta 1 inhibits cell growth does not interfere with the triggering of early mitogenic signal transduction mechanisms. Phospholipase C-catalyzed hydrolysis of phosphatidylcholine (PC) is a relatively late step in the cascade activated by growth factors. Therefore, conceivably activation of phospholipase C-catalyzed hydrolysis of PC could be the target of TGF-beta 1 action. In the study reported here, we demonstrate that TGF-beta 1 inhibits the coupling of ras p21 to the activation of PC hydrolysis, which appears to be critical for the antiproliferative effects of TGF-beta 1.
Collapse
|
40
|
Dominguez I, Marshall MS, Gibbs JB, García de Herreros A, Cornet ME, Graziani G, Diaz-Meco MT, Johansen T, McCormick F, Moscat J. Role of GTPase activating protein in mitogenic signalling through phosphatidylcholine-hydrolysing phospholipase C. EMBO J 1991; 10:3215-20. [PMID: 1655413 PMCID: PMC453045 DOI: 10.1002/j.1460-2075.1991.tb04884.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Recent evidence has accumulated showing that activation of PLC-catalysed hydrolysis of phosphatidylcholine (PC-PLC) is a critical step in mitogenic signal transduction both in fibroblasts and in oocytes from Xenopus laevis. The products of ras genes activate PC-PLC, bind guanine nucleotides, have intrinsic GTPase activity, and are regulated by a GTPase-activating protein (GAP). It has been suggested that, in addition to its regulatory properties, GAP may also be necessary for ras function as a downstream effector molecule. In this study, evidence is presented that strongly suggests that the functional interaction between ras p21 and GAP is sufficient and necessary for activation of maturation promoting factor (MPF) H1-kinase activity in oocytes, and that PC hydrolysis is critically involved in this mechanism. Therefore, we identify GAP as a further step required for signalling through PC-PLC, and necessary for the control of oocyte maturation in response to ras p21/insulin but not to progesterone.
Collapse
Affiliation(s)
- I Dominguez
- Medicina y Cirugía Experimental, Hospital General Gregorio Marañón, Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
García de Herreros A, Dominguez I, Diaz-Meco MT, Graziani G, Cornett ME, Guddal PH, Johansen T, Moscat J. Requirement of phospholipase C-catalyzed hydrolysis of phosphatidylcholine for maturation of Xenopus laevis oocytes in response to insulin and ras p21. J Biol Chem 1991; 266:6825-9. [PMID: 2016297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Recent studies have demonstrated the activation of phospholipase C-mediated hydrolysis of phosphatidylcholine both by growth factors and by the product of ras oncogene, ras p21. Also, evidence has been presented indicating that the stimulation of this phospholipid-degradative pathway is sufficient to activate mitogenesis in fibroblasts. In Xenopus laevis oocytes, microinjection of transforming ras p21 is a potent inducer of maturation, whereas microinjection of a neutralizing anti-ras p21 antibody specifically inhibits maturation induced by insulin but not by progesterone. The results presented here demonstrated that microinjection of phosphatidylcholine-hydrolyzing phospholipase C is sufficient to induce maturation of Xenopus laevis oocytes. Furthermore, microinjection of a neutralizing anti-phosphatidylcholine-hydrolyzing phospholipase C specifically blocks the maturation program induced by ras p21/insulin but not by progesterone.
Collapse
Affiliation(s)
- A García de Herreros
- Medicina y Cirugía Experimental, Hospital General Gregorio Marañón, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
42
|
García de Herreros A, Dominguez I, Diaz-Meco MT, Graziani G, Cornett ME, Guddal PH, Johansen T, Moscat J. Requirement of phospholipase C-catalyzed hydrolysis of phosphatidylcholine for maturation of Xenopus laevis oocytes in response to insulin and ras p21. J Biol Chem 1991. [DOI: 10.1016/s0021-9258(20)89574-x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
43
|
Cortés F, Dominguez I, Piñero J, Mateos JC. Adaptive response in human lymphocytes conditioned with hydrogen peroxide before irradiation with X-rays. Mutagenesis 1990; 5:555-7. [PMID: 2263213 DOI: 10.1093/mutage/5.6.555] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Cultured human lymphocytes were first exposed to a low 'conditioning' dose of hydrogen peroxide and, subsequently, irradiated with a 'challenge' dose of 1.5 Gy of X-rays in order to analyse the induction of an adaptive response to oxidative damage. A significant reduction in X-ray-induced chromosome damage was evident when H2O2 was given as a single 30 min pulse 24 h after setting up the cultures and the lymphocytes were exposed to X-rays at 48 h. In contrast, when the cells underwent a repeated exposure to H2O2 before irradiation the yield of aberrations was that expected from the combined treatment.
Collapse
Affiliation(s)
- F Cortés
- Departamento de Biología Celular, Facultad de Biología, Sevilla, Spain
| | | | | | | |
Collapse
|
44
|
Lagomarsino E, Pantoja H, Awad J, Tapia J, Dominguez I. [Proximal renal tubular acidosis]. Rev Chil Pediatr 1977; 48:169-75. [PMID: 616951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
45
|
|
46
|
Bergher de Bacalao E, Rivero A, Dominguez I. [Findings on dysplasia combined with in situ carcinoma of the cervix uteri]. Rev Obstet Ginecol Venez 1968; 28:355-373. [PMID: 5735269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|